Moderna, Inc. (MRNA) Stock Price & Analysis
Moderna, Inc. (MRNA) closed at USD 222.76 on Thursday, October 29, 2026, up 4.01% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 214.17; the Oct 29, 2026 session ranged USD 215.38–224.96 on volume of 10,673,110 shares. Market capitalization is $88.93B, with a 52-week range of USD 22.28–254.48 (NMS). Source: Nexqual, retrieved October 29, 2026 at 20:54 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MRNA.md
Key facts (MRNA)
- Last four reported quarters (through Jun 30, 2026): revenue $2.23B, net income -$3.15B (-141.4% margin), free cash flow -$1.24B (SEC filings).
- Insider open-market sales, last ~7 months: 11 Form 4 filings, $72.4M; 1 not under a Rule 10b5-1 plan ($434K); 2 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.96 on a 1–5 scale) (23 analysts), mean target USD 138.37 (range 45–251).
- Total return with dividends: 1Y +691.6% vs S&P 500 +14.4%; 5Y -35.5% vs S&P 500 +79.1%.
- Next earnings: 2026-11-06, EPS estimate USD -1.28, revenue estimate $891M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MRNA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $18.5B | $19.3B | $6.85B | $3.24B | $1.94B | $2.23B |
| Gross profit | $15.9B | $13.8B | $2.15B | $1.77B | $1.08B | — |
| Operating income | $13.3B | $9.42B | -$4.24B | -$3.94B | -$3.07B | -$3.32B |
| Net income | $12.2B | $8.36B | -$4.71B | -$3.56B | -$2.82B | -$3.15B |
| EPS (diluted) | $28.29 | $20.12 | -$12.33 | -$9.28 | -$7.26 | — |
| Free cash flow | $13.3B | $4.58B | -$3.83B | -$4.05B | -$2.06B | -$1.24B |
| Gross margin | 85.8% | 71.9% | 31.5% | 54.8% | 55.3% | — |
| Operating margin | 72.0% | 48.9% | -61.9% | -121.9% | -158.1% | -149.0% |
| Net margin | 66.1% | 43.4% | -68.8% | -110.0% | -145.2% | -141.4% |
| Revenue growth | +2200.2% | +4.3% | -64.4% | -52.7% | -39.9% | — |
| Cash + short-term investments | $10.7B | $9.90B | $8.60B | $7.03B | $5.80B | — |
| Total debt | — | — | — | $0K | $590M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MRNA)
P/S 39.9x · EV/Sales 37.9x · P/B 13.2x · FCF yield -1.40% · Earnings yield -3.54% · Net cash $4.55B · EV $84.4B
Insider sales (SEC Form 4, open-market, last ~7 months) (MRNA)
10 of 11 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-14…2026-10-15 | Hoge Stephen | President | 78,369 | $17.0M | 4.2% | Yes (adopted June 15, 2026) | Too little history (no open-market trades in 2025) |
| 2026-09-14…2026-09-15 | Hoge Stephen | President | 80,575 | $11.7M | 4.5% | Yes (adopted June 15, 2026) | Too little history (no open-market trades in 2025) |
| 2026-09-10 | Mock James M | Chief Financial Officer | 34,836 | $4.7M | 37% | Yes (adopted June 9, 2026) | Too little history (no open-market trades in 2025) |
| 2026-09-01 | Klinger Shannon Thyme | Chief Legal Officer | 3,471 | $486K | 4.4% | Yes (adopted September 9, 2025) | Too little history (no open-market trades in 2025) |
| 2026-08-05 | Bancel Stephane | Chief Executive Officer | 499,246 | $28.7M | 3.1% | Yes (adopted May 4, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-07-15 | Hoge Stephen | President | 53,336 | $3.6M | 3.1% | Yes (adopted November 13, 2025) | Too little history (no open-market trades in 2025) |
| 2026-06-15 | Hoge Stephen | President | 53,336 | $2.7M | 3.1% | Yes (adopted November 13, 2025) | Too little history (no open-market trades in 2025) |
| 2026-06-04 | Klinger Shannon Thyme | Chief Legal Officer | 3,471 | $174K | 4.5% | Yes (adopted September 9, 2025) | Too little history (no open-market trades in 2025) |
| 2026-05-21 | Afeyan Noubar | Director | 9,263 | $434K | 0.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-15 | Hoge Stephen | President | 53,336 | $2.6M | 3.2% | Yes (adopted November 13, 2025) | Too little history (no open-market trades in 2025) |
| 2026-05-01 | Hussain Abbas | Director | 5,682 | $265K | 32% | Yes (adopted September 5, 2025) | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (MRNA)
Consensus Hold (mean 2.96 on a 1–5 scale), 23 analysts; mean target USD 138.37 (low 45, high 251).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-27 | William Blair | Downgrade | Outperform → Market Perform | |
| 2026-10-26 | Piper Sandler | Target raised | Overweight | $167 → $230 |
| 2026-10-21 | TD Cowen | Target raised | Hold | $40 → $90 |
| 2026-10-15 | Goldman Sachs | Target raised | Neutral | $120 → $137 |
| 2026-10-07 | Morgan Stanley | Target raised | Equal-Weight | $89 → $95 |
| 2026-09-30 | Citigroup | Downgrade | Neutral → Sell | $60 → $80 |
| 2026-09-03 | Rothschild & Co | Downgrade | Neutral → Sell | $40 → $81 |
| 2026-08-28 | Argus Research | Upgrade | Hold → Buy | $180 |
| 2026-08-25 | Wolfe Research | Upgrade | Underperform → Peer Perform | |
| 2026-08-24 | Barclays | Target raised | Equal-Weight | $48 → $125 |
| 2026-08-21 | JP Morgan | Target raised | Underweight | $40 → $77 |
| 2026-08-20 | Goldman Sachs | Target raised | Neutral | $67 → $120 |
Total return (dividends reinvested) (MRNA)
| 1Y (from 2025-10-30) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +691.6% | -35.5% |
| S&P 500 (SPY) | +14.4% | +79.1% |
| Per year | +697.3% | -8.4% |
| Volatility (annualized) | 129.9% | 77.8% |
| Max drawdown | -34.2% (Jul 2026→Aug 2026) | -93.2% (Oct 2021→Sep 2025) |
MRNA earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Jul 31, 2026 | Quarter ended Jun 30, 2026 | −$1.97 | −$2.06 | Beat +4.4% | -4.8% |
| May 1, 2026 | Quarter ended Mar 31, 2026 | −$3.40 | −$3.88 | Beat +12.4% | +3.0% |
| Feb 13, 2026 | Quarter ended Dec 31, 2025 | −$2.11 | −$2.60 | Beat +18.8% | +9.5% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | −$2.11 | −$2.60 | Beat +18.8% | +15.5% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.51 | −$2.18 | Beat +76.6% | +4.2% |
| Aug 1, 2025 | — | — | — | — | -6.5% |
| May 1, 2025 | — | — | — | — | -3.3% |
| Feb 14, 2025 | — | — | — | — | +12.0% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
MRNA recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 30, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “(b) and (c) On September 30, 2026, Moderna, Inc. ("Moderna" or the "Company") announced the appointment of Juan Andres as its Chief Operating Officer ("COO") effective October 5, 2026. In this newly created role, Mr. Andres will support the increasing scale and diversification of the Company and will report to Chief Executive Officer Stephane Bancel and serve on the Company's Executive Committee. Mr. Andres, 62, previously spent nearly six years at Moderna, including serving as its Chief Technical Operations and…” |
| Sep 1, 2026 | 8-K | Entered a material agreement; New debt or off-balance-sheet obligation; Unregistered sale of shares; Other material event “Indenture and Notes On September 1, 2026, Moderna, Inc. (the "Company") completed its previously announced private offering (the "Offering") of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032 (the "Notes"), including the exercise in full of the initial purchasers' option to purchase up to an additional $400,000,000 aggregate principal amount of the Notes. The Notes were issued pursuant to an indenture, dated September 1, 2026 (the "Indenture"), between the Company and U.S. Bank…” |
| Aug 12, 2026 | Schedule 13G | Capital World Investors: 5.6% of shares, passive 5%+ holder |
| Aug 6, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 13.1% of shares, passive 5%+ holder (amended) |
| Jul 31, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Jul 31, 2026 | 8-K | Quarterly results |
| Jul 24, 2026 | Schedule 13G/A | BAILLIE GIFFORD & CO: 4.6% of shares, passive 5%+ holder (amended) |
| Jul 8, 2026 | 8-K | Director or executive officer change, or pay arrangement; Regulation FD disclosure “(d) On July 6, 2026 , the Board of Directors (the "Board") of Moderna, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating and Corporate Governance Committee"), appointed Michael McDonnell to the Board, effective July 8, 2026. Mr. McDonnell has more than 35 years of financial leadership and public company experience, most recently serving as Chief Financial Officer of Biogen Inc. from August 2020 through February 2025. He previously…” |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
MRNA revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Net product sales | $94.0M | 64.8% | -17.5% |
| — COVID (part of Net product sales) | $91.0M | 62.8% | -20.2% |
| — RSV (part of Net product sales) | $3.0M | 2.1% | — |
| Other revenue | $51.0M | 35.2% | +82.1% |
| — Stand-ready manufacturing revenue (part of Other revenue) | $31.0M | 21.4% | +82.4% |
| — Collaboration Arrangement, Including Arrangements With Affiliate (part of Other revenue) | $15.0M | 10.3% | +275.0% |
| — Licensing and royalty revenue (part of Other revenue) | $3.0M | 2.1% | +50.0% |
| — Grant revenue (part of Other revenue) | $2.0M | 1.4% | -60.0% |
| Total revenue | $145.0M | 100% | — |
MRNA revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $1.20B | 61.7% | -32.8% |
| Rest Of World | $692.0M | 35.6% | -18.9% |
| Europe | $53.0M | 2.7% | -91.1% |
| Total revenue | $1.94B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MRNA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Merck (MRK) | “We are advancing intismeran in collaboration with Merck, with eight Phase 2 and Phase 3 clinical trials underway across multiple tumor types.” |
| Partner | Immatics N.V. (IMTX) | “We have also expanded our oncology portfolio with early-stage programs, including mRNA-4106 (a cancer antigen therapy), mRNA-2808 (a T-cell engager), and mRNA-4203 (a cell-therapy enhancer). mRNA-4203 is being developed in collaboration with Immatics.” |
| Partner | Vertex Pharmaceuticals | “In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated, and Vertex Pharmaceuticals (Europe) Limited (together, Vertex).” |
| Partner | ARES CAPITAL CORP (ARCC) | “A failure to comply with the covenants in our credit agreement with lenders led by Ares Capital Corporation, as administrative agent, could result in an event of default, which, if not cured or waived, could have a material, adverse effect on our business, financial condition, and results of operations.” |
| Partner | OpenAI | “In early 2023, we began a collaboration with OpenAI to co-innovate with a shared vision of AI's transformative potential in the future of business and healthcare.” |
| Competitor | Pfizer (PFE) | “We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology.” |
Quoted from the company's 10-K filed Feb 20, 2026.
Companies that name MRNA in their SEC reports
| Relationship to MRNA | Company | Filing | Sentence |
|---|---|---|---|
| competitor | GeoVax Labs, Inc. (GOVX) | 10-K Apr 15, 2026 | “We face general market competition from several subsectors of the vaccine development field, including large, multinational pharmaceutical companies including Sanofi, GSK, Merck, Mitsubishi Tanabe, Takeda, and Pfizer; mid-size pharmaceutical companies and emerging biotechnology companies including Dynavax, Novavax, Moderna, BioNTech and Bavarian Nordic; and academic and not-for-profit vaccine researchers and devel…” |
| partner | Autolus Therapeutics plc (AUTL) | 10-K Mar 27, 2026 | “We have collaboration and license agreements with, for example, BioNTech SE, Cabaletta Bio Inc., Moderna Inc., Bristol-Myers Squibb Company, and others.” |
| competitor | BioCardia, Inc. (BCDA) | 10-K Mar 24, 2026 | “The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market, including AstraZeneca, Bayer, Blue Rock Therapeutics, Bristol-Myers Squibb, Lisata Therapeutics, Capricor Therapeutics, Celixir, Celyad, Daiichi Sankyo, Fuji Film, Mesoblast, Moderna, Orizuru Therapeutics, Sana Biotechnology, Takeda Pharmaceuticals, Tenaya Therapeutics, Terumo, Vericel Cor…” |
| partner | Silexion Therapeutics Corp (SLXN) | 10-K Mar 17, 2026 | “Other companies with selective KRAS inhibitors include AstraZeneca (in collaboration with Usynova), BioNTech, Roche, Merck/Moderna, Boehringer and Gilead.” |
| partner | CytomX Therapeutics, Inc. (CTMX) | 10-K Mar 16, 2026 | “We currently have several strategic alliances with major multinational drug companies, including Amgen, Inc. ("Amgen"), Bristol Myers Squibb, Astellas Pharma Inc. ("Astellas"), Regeneron Pharmaceuticals Inc. ("Regeneron"), and ModernaTX, Inc., a wholly owned subsidiary of Moderna, Inc ("Moderna").” |
| competitor | Coya Therapeutics, Inc. (COYA) | 10-K Mar 16, 2026 | “Competitor companies developing Biologic approaches to enhancing Tregs, leveraging IL-2 formulations, include: Amgen (AMGN) (IL-2 mutein for GVHD and autoimmune diseases), Nektar Therapeutics (NKTR) (Pegylated IL-2 for autoimmune diseases), Merck (MRK) (IL-2 mutein for autoimmune diseases), Xencor (XNCR) (IL-2 Fc Fusion Protein for autoimmune diseases), Cue Biopharma (CUE) (IL-2 bispecific for GVHD and autoimmune …” |
| competitor | ORAGENICS INC (OGEN) | 10-K Mar 16, 2026 | “AstraZeneca, and Moderna, among others, compete in the same or similar markets.” |
| competitor | BioNTech SE (BNTX) | 20-F Mar 10, 2026 | “developed by Moderna, Inc. and Novavax, Inc. Our competitors pursuing vaccine candidates may have greater” |
| partner | Immatics N.V. (IMTX) | 20-F Mar 5, 2026 | “In parallel to our proprietary development, we are collaborating with Moderna to evaluate the combination of anzu-cel (IMA203) with Moderna's PRAME cell therapy enhancer, mRNA-4203, in an ongoing Phase 1 trial.” |
| partner | Metagenomi Therapeutics, Inc. (MGX) | 10-K Mar 5, 2026 | “On April 26, 2024 (the "Termination Date"), we and ModernaTx, Inc. ("Moderna") mutually terminated the Strategic Collaboration and License Agreement, dated October 29, 2021 (the "Moderna Agreement"), by and between us and Moderna.” |
| competitor | Invivyd, Inc. (IVVD) | 10-K Mar 5, 2026 | “Alternative COVID-19 prevention competition exists from mRNA vaccine manufacturers Moderna and Pfizer-BioNTech, as well as protein subunit vaccine from Novavax (authorized for people 12 years and older).” |
| partner | Ocugen, Inc. (OCGN) | 10-K Mar 4, 2026 | “Companies such as Pfizer Inc./BioNTech SE, Moderna, Inc., CureVac N.V in partnership with GSK plc, Vivaldi Biosciences Inc., and Novavax, Inc. are also in the process of developing a combination vaccine that will protect against COVID-19 and the seasonal flu.” |
| competitor | Prime Medicine, Inc. (PRME) | 10-K Mar 3, 2026 | “Other companies have announced intentions to enter the gene editing field, such as Moderna, Inc. and Pfizer Inc. Most recently, new epigenetic editing companies have emerged, such as Moonwalk Biosciences, Inc., nChroma Bio, Inc. and Tune Therapeutics, Inc. In addition, we face competition from companies utilizing gene therapy, oligonucleotides and cell therapy therapeutic approaches.” |
| partner | Caris Life Sciences, Inc. (CAI) | 10-K Mar 3, 2026 | “Our molecular profiling solutions and the data generated by our multi-omic technology platform provide value to our biopharma partners, such as Moderna, AbbVie, Xencor, Merck KGaA and Genentech, through partnerships that aim to increase the probability of technical and regulatory success of their therapeutic pipelines.” |
| competitor | Arcturus Therapeutics Holdings Inc. (ARCT) | 10-K Mar 3, 2026 | “We are aware of product candidates of the following companies that we consider as competitors or future competitors to ARCT-032: Moderna/Vertex, Recode Therapeutics, Eloxx Pharmaceuticals, 4DMT, Spirovant, SalioGen, Splisense, Krystal Biotech, Sionna and Enterprise Therapeutics.” |
MRNA customer concentration
In the period ended Dec 31, 2025, 3 direct customers each accounted for at least 10% (15%, 13%, 11%) of revenue, per the company's 10-K filed Feb 20, 2026. The company does not name them.
MRNA company outlook (results filed Jul 31, 2026)
- “The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026. 2026 Financial Framework Revenue: The Company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international.”
- “Moderna expects approximately 55% of its second half 2026 revenue to be recognized in the third quarter.”
- “Cost of Sales: Cost of sales for 2026 is expected to be approximately $1.7 billion, lowered from approximately $1.8 billion, and including the $0.9 billion non-recurring litigation settlement charge.”
- “Research and Development Expenses: Research and development expenses for 2026 are now anticipated to be approximately $2.9 billion, lowered from approximately $3.0 billion.”
Quoted word-for-word from the SEC 8-K results press release.
MRNA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.28 | $-1.22 | −$0.06 | $891.3M | 15 |
| Next quarter (ends Dec 2026) | $-1.86 | $-2.06 | +$0.20 | $675.4M | 13 |
| Current fiscal year (ends Dec 2026) | $-8.50 | $-8.67 | +$0.17 | $2.10B | 21 |
| Next fiscal year (ends Dec 2027) | $-4.90 | $-4.75 | −$0.14 | $2.44B | 19 |
MRNA options: expected move
Options price a move of about ±11.5% (±$25.30) by Nov 6, 2026, which includes earnings on Nov 6, 2026. Over the last 8 reports the stock moved ±7.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Oct 30, 2026 | 1 | 96.2% | ±4.2% |
| Nov 6, 2026 | 8 | 96.0% | ±11.5% |
| Nov 13, 2026 | 15 | 93.4% | ±15.2% |
| Nov 20, 2026 | 22 | 87.7% | ±17.2% |
| Nov 27, 2026 | 29 | 84.8% | ±19.1% |
| Dec 4, 2026 | 36 | 82.5% | ±20.7% |
| Dec 11, 2026 | 43 | 81.3% | ±22.3% |
| Dec 18, 2026 | 50 | 81.6% | ±24.1% |
30-day implied volatility 83.2% vs 99.9% realized over the last 30 trading days. Put/call ratio (volume) 0.74. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 20:54 UTC)
| Price | USD 222.76 |
|---|---|
| Change | ▲ 4.01% (up) |
| Previous Close | USD 214.17 |
| Open | USD 216.26 |
| Day Range | USD 215.38 – 224.96 |
| 52-Week Range | USD 22.28 – 254.48 |
| Volume | 10,673,110 shares |
| Market Cap | $88.93B |
| Exchange | NMS |
Technical Analysis (MRNA)
Nexqual's technical model rates MRNA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 20:54 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.99 (neutral) |
| vs SMA50 | Above (USD 180.72) |
| MACD | 10.72 (positive) |
Analyst Ratings (MRNA)
Wall Street analysts rate MRNA "Hold" based on 23 analysts, with a mean price target of USD 138.37 (range USD 45–251), per Nexqual as of October 29, 2026 at 20:54 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 138.37 |
| High Target | USD 251 |
| Low Target | USD 45 |
| Buy / Hold / Sell | 4 / 16 / 3 |
Earnings (MRNA)
| Next Earnings Date | 2026-11-06 |
|---|---|
| EPS Estimate | USD -1.35 |
| Revenue Estimate | $891.31M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.97 vs est -2.06 ▲ beat |
| 2026-03-31 | USD -3.4 vs est -3.88 ▲ beat |
| 2025-12-31 | USD -2.11 vs est -2.6 ▲ beat |
| 2025-09-30 | USD -0.51 vs est -2.18 ▲ beat |
Source: Nexqual, October 29, 2026 at 20:54 UTC.
Financials & Fundamentals (MRNA)
| Total Revenue | $2.23B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.10% |
| Gross Margin | -66.02% |
| Operating Margin | -557.93% |
| Profit Margin | -141.43% |
| ROE | -39.00% |
| Debt / Equity | 0.19 |
| Current Ratio | 2.3 |
| Total Cash | $5.14B |
| Total Debt | $1.29B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$1.24B (-55.8% of revenue) |
Source: Nexqual, October 29, 2026 at 20:54 UTC.
Financial Health Score (MRNA)
Nexqual rates Moderna, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 20:54 UTC.
| Growth | Critical — Revenue -40% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $5.14B cash and investments vs $591M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$1.24B (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -47%, ROA -28.7% (last 4 quarters, SEC) |
Ownership (MRNA)
| Insider Ownership | +7.36% |
|---|---|
| Institutional Ownership | +80.54% |
| Shares Outstanding | 399.24M |
| Float | 371.98M |
| Short % of Float | +9.98% |
Source: Nexqual, October 29, 2026 at 20:54 UTC.
Leadership (MRNA)
Moderna, Inc. is led by Stéphane Bancel, CEO & Director, per Nexqual as of October 29, 2026 at 20:54 UTC.
| CEO & Director | Stéphane Bancel |
|---|---|
| President | Stephen Hoge |
| Chief Financial Officer | James M. Mock |
| Chief Operating Officer | Juan Andres |
| Senior Vice President of Commercial Vaccines | Patrick Norman Bergstedt |
Major Backers & Investors (MRNA)
Notable institutional backers of Moderna, Inc. include FMR, LLC, Capital Group, Baillie Gifford, according to Nexqual as of October 29, 2026 at 20:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 12.99% |
| Capital Group | 5.58% |
| Baillie Gifford | 4.56% |
| Growth Fund of America | 3.75% |
| Fidelity | 3.36% |
| Morgan Stanley | 2.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.71% |
| BlackRock | 7.66% |
| State Street | 3.94% |
| Geode Capital | 2.43% |
Source: Nexqual, October 29, 2026 at 20:54 UTC.
From Moderna, Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Examples of tools we developed by using our platform include proprietary LNP formulations that address the steps of mRNA delivery, including cell uptake, endosomal escape, and subsequent lipid metabolism, and for avoidance of counterproductive interactions with the immune system.
- We pursue updated vaccine compositions based on guidance from the FDA, and other regulatory bodies including European Medicines Agency (EMA) and the World Health Organization (WHO), with the goal of broadening vaccine-induced immunity and providing protection against circulating SARS-CoV-2 variants.
- We have developed an RSV vaccine (mRNA-1345 or mRESVIA) for adults. mRESVIA encodes an engineered form of the RSV F protein stabilized in the prefusion conformation and is formulated in our proprietary LNP.
- We filed for FDA approval for mRNA-1083 in November 2024 and also submitted regulatory applications in other geographies, including the EU, Canada, Australia and the UK.
Partnerships
- In September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement).
- In January 2026, we entered into a strategic collaboration with Recordati, an international pharmaceutical group, to advance mRNA-3927 through the final stages of clinical development and, if approved, global commercialization.
Legal & Regulatory Risks (Item 1A, quoted)
- Any products we may develop are subject to comprehensive regulation by the FDA and comparable foreign regulators.
- The FDA and comparable foreign regulators have substantial discretion in the approval process and may refuse to accept any marketing approval application or may decide that our data are insufficient for marketing approval and require additional preclinical, clinical or other studies.
- We may experience delays in enrolling participants in our clinical trials.
- Adverse events reported with respect to gene therapies could adversely impact one or more of our programs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | USD 818.77 | ▲ 0.68% |
| VRTX | Vertex Pharmaceuticals Incorpor | USD 540 | ▲ 1.95% |
| ARGX | argenx SE | USD 897.85 | ▲ 0.68% |
| ONC | BeOne Medicines Ltd. | USD 371.56 | ▼ 0.48% |
| RVMD | Revolution Medicines, Inc. | USD 190.27 | ▲ 0.82% |
| RPRX | Royalty Pharma plc | USD 65.93 | ▲ 1.71% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 20:54 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt